In the Review entitled “Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex” by C Craddock, J Anson, P Chu, A Dodgson, N Duncan, C Gomez, J Mehta, S Sadullah, C Subudhi and J-L Yin published in the January 2010 issue of Expert Opinion on Drug Safety (Expert Opin. Drug Saf. (2010) 9(1):139-147), it has been brought to the editor's attention that there was an error in Section 3.2.1 on page 142.
The bullet points in this section should have read as follows:
ABLC should be infused at 2.5 mg/kg/h (B II)
The patient should be closely monitored for any type of DDR associated with ABLC (D IV)
Fever and chills can be controlled by reducing the speed of the infusion to over 3 h (infusion rate of 1.6 mg/kg/h) (C III).
The authors, editors and publisher sincerely regret any inconvenience this may have caused our readers.